Loading
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Previous close
$2.28
−$0.12 · -5.00%
After-hours
$2.30
+$0.02 · +0.88%
Sep 8, 6:15 PM ET
Regular session · ET · Market data may be delayed.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Day range
Current $2.28
52-week range
Current $2.28
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
17
Overpriced
Sentiment
53
Mixed
Risk
66
High Risk
Momentum
40
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Silo Pharma Inc. operates as a developmental-stage biopharmaceutical firm dedicated to creating treatments for a variety of underserviced medical conditions. These include stress-related psychiatric disorders, persistent pain syndromes, and diseases impacting the central nervous system (CNS). The company's approach combines both traditional and psychedelic therapies, with a strong emphasis on innovative formulations and advanced drug delivery systems. Leading its pipeline is SPC-15, an intranasal treatment engineered to address post-traumatic stress disorder (PTSD) and anxiety disorders stemming from stress. Another key development is SP-26, a time-release, ketamine-loaded implant designed to provide relief for fibromyalgia and chronic pain. Furthermore, Silo Pharma is advancing two preclinical programs: SPC-14, an intranasal compound targeting Alzheimer's disease, and SPU-16, a CNS-homing peptide intended for the management of multiple sclerosis (MS). The company's research and development efforts frequently involve collaborations with prominent academic institutions such as Columbia University and the University of Maryland, Baltimore. Founded in 2010, the company adopted its current name, Silo Pharma, Inc., in September 2020, having previously operated as Uppercut Brands, Inc. Silo Pharma is headquartered in Sarasota, Florida.
Day range
Current $2.28
52-week range
Current $2.28
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 72.1K USD | 72.1K USD | 72.1K USD | 72.1K USD | 71.26K USD |
| Cost of goods sold | 886.06K USD | 5.84K USD | 5.84K USD | 5.84K USD | 5K USD |
| Gross profit | −813.96K USD | 66.26K USD | 66.26K USD | 66.26K USD | 66.26K USD |
| Research and development | 2.16M USD | 2.37M USD | 845.09K USD | 1.29M USD | 693.91K USD |
| Selling, general, and administrative | 2.15M USD | 2.4M USD | 3.08M USD | 2.43M USD | 2.27M USD |
| Operating expenses | 3.47M USD | 4.77M USD | 3.92M USD | 3.69M USD | 2.81M USD |
| Interest income | 193.91K USD | 333.17K USD | 398.53K USD | 72.64K USD | 1.21K USD |
| Interest expense | 37.3K USD | 5.08K USD | 4.87K USD | 2.2K USD | 3.04K USD |
| Depreciation and amortization | 11.44K USD | 6.19K USD | — | — | — |
| Operating income | −4.28M USD | −4.71M USD | −3.86M USD | −3.63M USD | −2.74M USD |
| Net income | −4.23M USD | −4.39M USD | −3.7M USD | −3.91M USD | 3.9M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
